{"id":3171,"date":"2016-07-05T12:50:01","date_gmt":"2016-07-05T12:50:01","guid":{"rendered":"http:\/\/blogs.sld.cu\/oserranob\/?p=3171"},"modified":"2016-07-06T18:18:34","modified_gmt":"2016-07-06T18:18:34","slug":"gen-protector-para-cardiopatia-isquemica","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/oserranob\/2016\/07\/05\/gen-protector-para-cardiopatia-isquemica\/","title":{"rendered":"Gen protector para cardiopat\u00eda isqu\u00e9mica"},"content":{"rendered":"<p style=\"text-align: justify\"><a href=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2016\/07\/STM-CHD.jpg\"><img loading=\"lazy\" class=\"alignleft size-full wp-image-3209\" style=\"border-width: 1px;margin: 5px\" src=\"https:\/\/blogs.sld.cu\/oserranob\/files\/2016\/07\/STM-CHD.jpg\" alt=\"STM CHD\" width=\"85\" height=\"76\" \/><\/a>Una variante del gen <a title=\"Informaci\u00f3n sobre el gen en Gene\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/gene\/2740\" target=\"_blank\">GLP1R<\/a> (<a title=\"Informaci\u00f3n sobre el gen en Gene\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/gene\/2740\" target=\"_blank\"><em>glucagon-like peptide-1 receptor<\/em><\/a>), diana de varios tratamientos para la <a title=\"Informaci\u00f3n sobre la enfermedad en OMIM\" href=\"http:\/\/omim.org\/entry\/125853\" target=\"_blank\">diabetes mellitus<\/a>, se ha asociado con menor riesgo de <a title=\"Informaci\u00f3n sobre la enfermedad en OMIM\" href=\"http:\/\/omim.org\/entry\/607339\" target=\"_blank\">enfermedad coronaria<\/a>. Los detalles aparecen en Scott RA, Freitag DF, Li L, Chu AY, Surendran P, Young R,<em> et al<\/em>. <a title=\"Resumen en ingl\u00e9s\" href=\"http:\/\/stm.sciencemag.org\/content\/8\/341\/341ra76.short\" target=\"_blank\">A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease<\/a>. Science Translational Medicine\u00a0 01 Jun 2016;8(341):341ra76.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Una variante del gen GLP1R (glucagon-like peptide-1 receptor), diana de varios tratamientos para la diabetes mellitus, se ha asociado con menor riesgo de enfermedad coronaria. Los detalles aparecen en Scott RA, Freitag DF, Li L, Chu AY, Surendran P, Young R, et al. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant [&hellip;]<\/p>\n","protected":false},"author":125,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[13,15,23,29],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3171"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/comments?post=3171"}],"version-history":[{"count":4,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3171\/revisions"}],"predecessor-version":[{"id":3211,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/posts\/3171\/revisions\/3211"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/media?parent=3171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/categories?post=3171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/oserranob\/wp-json\/wp\/v2\/tags?post=3171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}